Patents by Inventor Girish G. Kore
Girish G. Kore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131018Abstract: Pharmaceutical compositions suitable for oral administration (such as a tablet or a capsule) are provided, which comprise a therapeutically effective amount of an amorphous solid dispersion of cabozantinib, e.g., for treating a proliferative disorder. Preferably, the amorphous solid dispersion consists of (a) cabozantinib or a pharmaceutically acceptable salt thereof (such as cabozantinib (S)-malate); (b) at least one pharmaceutically acceptable carrier selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine and vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), and mixtures thereof; (c) a pore-forming agent; and (d) a plasticizer.Type: ApplicationFiled: November 29, 2023Publication date: April 25, 2024Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20240009188Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: September 15, 2023Publication date: January 11, 2024Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Sandeep JAIN, Hanimi Reddy BAPATU
-
Patent number: 11793809Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 20, 2020Date of Patent: October 24, 2023Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Publication number: 20230285368Abstract: Liquid pharmaceutical compositions of apixaban or pharmaceutically acceptable salts thereof are described. More specifically, stable oral liquid pharmaceutical compositions of apixaban for oral administration are provided, wherein the composition is stable for extended periods of time. More specifically, stable liquid pharmaceutical compositions of apixaban at concentrations of 0.4 mg/mL or more are provided. Stable oral liquid compositions of apixaban, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by apixaban are disclosed.Type: ApplicationFiled: March 6, 2023Publication date: September 14, 2023Applicant: Slayback Pharma LLCInventors: Sushant Omprakash Dube, Girish G. Kore, Naga Venkata Durga Prasad Ketha, Sumitra Ashokkumar Pillai, Praveen Kumar Subbappa
-
Publication number: 20230270736Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: May 5, 2023Publication date: August 31, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Patent number: 11679105Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 10, 2023Date of Patent: June 20, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Publication number: 20230181561Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: February 10, 2023Publication date: June 15, 2023Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Patent number: 11590122Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: GrantFiled: February 16, 2022Date of Patent: February 28, 2023Assignee: SLAYBACK PHARMA LLCInventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
-
Publication number: 20220387418Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: August 10, 2022Publication date: December 8, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220362235Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: July 18, 2022Publication date: November 17, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220280500Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: May 25, 2022Publication date: September 8, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Publication number: 20220265633Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.Type: ApplicationFiled: February 16, 2022Publication date: August 25, 2022Applicant: SLAYBACK PHARMA LLCInventors: Sushant Omprakash DUBE, Suprit Dilip SAOJI, Pankaj Kisan CHATKI, Sumitra Ashokkumar PILLAI, Girish G. KORE
-
Patent number: 11103503Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: January 28, 2020Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Patent number: 11103502Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: November 27, 2019Date of Patent: August 31, 2021Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20210077485Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 20, 2020Publication date: March 18, 2021Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Patent number: 10874671Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: GrantFiled: February 18, 2020Date of Patent: December 29, 2020Assignee: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Sandeep Jain, Hanimi Reddy Bapatu
-
Publication number: 20200261449Abstract: Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Cmax, AUC0-t and/or AUC0-infinity) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: February 18, 2020Publication date: August 20, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Sandeep JAIN, Hanimi Reddy BAPATU
-
Publication number: 20200222394Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: November 27, 2019Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. Jain, Ajay Kumar Singh, Praveen Kumar Subbappa, Keerthi Priya, Girish Kumar Jain, Girish G. Kore, Hanimi Reddy Bapatu, Sandeep Jain
-
Publication number: 20200222395Abstract: Solid dispersions of lurasidone or a pharmaceutically acceptable salt thereof are described, as well as pharmaceutical formulations thereof, and methods for making such formulations. Preferably, the solid dispersions are prepared by hot-melt extrusion or spray-drying, and comprise lurasidone with a pharmaceutically acceptable carrier (e.g., hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), polyvinyl pyrrolidine vinyl acetate (PVP/VA) copolymer, hydroxypropyl methylcellulose phthalate (HPMCP), or mixtures thereof). The pharmaceutical composition may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., Tmax, Cmax, AUC0-t and/or AUC0-infinity) of lurasidone, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.Type: ApplicationFiled: January 28, 2020Publication date: July 16, 2020Applicant: SLAYBACK PHARMA LLCInventors: Paras P. JAIN, Ajay Kumar SINGH, Praveen Kumar SUBBAPPA, Keerthi PRIYA, Girish Kumar JAIN, Girish G. KORE, Hanimi Reddy BAPATU, Sandeep JAIN